Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases
Aim: To investigate the role of immunotherapy in the overall survival (OS) of gastrointestinal cancer patients who have liver metastases at the time of the primary site cancer diagnosis.Materials & methods: Survival outcome was compared between groups with immunotherapy and groups without immuno...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2024-12-01
|
| Series: | Hepatic Oncology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20450923.2024.2403323 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832581953334804480 |
|---|---|
| author | Taoyuan M Beninato Saber A Amin Michael J Baine Chi Lin |
| author_facet | Taoyuan M Beninato Saber A Amin Michael J Baine Chi Lin |
| author_sort | Taoyuan M Beninato |
| collection | DOAJ |
| description | Aim: To investigate the role of immunotherapy in the overall survival (OS) of gastrointestinal cancer patients who have liver metastases at the time of the primary site cancer diagnosis.Materials & methods: Survival outcome was compared between groups with immunotherapy and groups without immunotherapy.Results: Chemoimmunotherapy was associated with improved OS (hazard ratio [HR] 0.768; 95% CI 0.739–0.800; p < 0.001) compared with chemotherapy alone. Radiotherapy to the primary site plus chemoimmunotherapy was also associated with improved OS (HR 0.796; 95% CI 0.705–0.898; p < 0.001) compared to chemoradiation. Chemoimmunotherapy with radiotherapy to metastatic sites (except liver) was associated with improved OS (HR 0.771; 95% CI 0.706–0.842; p < 0.001) compared to chemoradiation.Conclusion: Immunotherapy plus chemotherapy or chemoradiation was associated with improved OS compared with chemotherapy or chemoradiation without immunotherapy. |
| format | Article |
| id | doaj-art-5c5fa4a879f0444e86dabe264bd7d05f |
| institution | Kabale University |
| issn | 2045-0923 2045-0931 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis |
| record_format | Article |
| series | Hepatic Oncology |
| spelling | doaj-art-5c5fa4a879f0444e86dabe264bd7d05f2025-01-30T06:49:32ZengTaylor & FrancisHepatic Oncology2045-09232045-09312024-12-0111110.1080/20450923.2024.2403323Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastasesTaoyuan M Beninato0Saber A Amin1Michael J Baine2Chi Lin3College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USADepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USADepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USADepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USAAim: To investigate the role of immunotherapy in the overall survival (OS) of gastrointestinal cancer patients who have liver metastases at the time of the primary site cancer diagnosis.Materials & methods: Survival outcome was compared between groups with immunotherapy and groups without immunotherapy.Results: Chemoimmunotherapy was associated with improved OS (hazard ratio [HR] 0.768; 95% CI 0.739–0.800; p < 0.001) compared with chemotherapy alone. Radiotherapy to the primary site plus chemoimmunotherapy was also associated with improved OS (HR 0.796; 95% CI 0.705–0.898; p < 0.001) compared to chemoradiation. Chemoimmunotherapy with radiotherapy to metastatic sites (except liver) was associated with improved OS (HR 0.771; 95% CI 0.706–0.842; p < 0.001) compared to chemoradiation.Conclusion: Immunotherapy plus chemotherapy or chemoradiation was associated with improved OS compared with chemotherapy or chemoradiation without immunotherapy.https://www.tandfonline.com/doi/10.1080/20450923.2024.2403323gastrointestinal cancerimmunotherapyliver metastasesGI primaryNational Cancer Databaseoverall survival |
| spellingShingle | Taoyuan M Beninato Saber A Amin Michael J Baine Chi Lin Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases Hepatic Oncology gastrointestinal cancer immunotherapy liver metastases GI primary National Cancer Database overall survival |
| title | Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases |
| title_full | Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases |
| title_fullStr | Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases |
| title_full_unstemmed | Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases |
| title_short | Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases |
| title_sort | role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases |
| topic | gastrointestinal cancer immunotherapy liver metastases GI primary National Cancer Database overall survival |
| url | https://www.tandfonline.com/doi/10.1080/20450923.2024.2403323 |
| work_keys_str_mv | AT taoyuanmbeninato roleofimmunotherapyintheoverallsurvivalofgastrointestinalcancerpatientswithlivermetastases AT saberaamin roleofimmunotherapyintheoverallsurvivalofgastrointestinalcancerpatientswithlivermetastases AT michaeljbaine roleofimmunotherapyintheoverallsurvivalofgastrointestinalcancerpatientswithlivermetastases AT chilin roleofimmunotherapyintheoverallsurvivalofgastrointestinalcancerpatientswithlivermetastases |